Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient

BMC Cancer

Jian Zhang⁴  Yuhao Shi⁴  Emilie Lalonde⁴  Lili Li²  Luca Cavallone²  Alex Ferenczy³  Walter H Gotlieb¹  William D Foulkes¹  Jacek Majewski⁴ 

[1] Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada

[2] Program in Cancer Genetcs, Departments of Oncology and Human Genetics, McGill University, Montreal, QC, Canada

[3] Departments of Pathology, McGill University and Jewish General Hospital, 546 Pine Avenue West, Montreal, QC H2W 1S6, Canada

[4] Genome Quebec Innovation Centre, Montreal, QC, Canada

关键词: Chromosomal rearrangements;    Tumor suppressor genes;    Next generation sequencing;    Hereditary cancer;    Gynecological cancer;    Driver mutations;   

Others  :  1079844
DOI  :  10.1186/1471-2407-13-146

 received in 2012-10-17, accepted in 2013-03-13,  发布年份 2013

【 摘 要 】

Background

Ovarian carcinoma is a common, and often deadly, gynecological cancer. Mutations in BRCA1 and BRCA2 genes are present in at least a fifth of patients. Uncovering other genes that become mutated subsequent to BRCA1/BRCA2 inactivation during cancer development will be helpful for more effective treatments.

Methods

We performed exome sequencing on the blood, primary tumor, omental metastasis and recurrence following therapy with carboplatin and paclitaxel, from a patient carrying a BRCA1 S1841R mutation.

Results

We observed loss of heterozygosity in the BRCA1 mutation in the primary and subsequent tumors, and somatic mutations in the TP53 and NF1 genes were identified, suggesting their role along with BRCA1 driving the tumor development. Notably, we show that exome sequencing is effective in detecting large chromosomal rearrangements such as deletions and amplifications in cancer. We found that a large deletion was present in the three tumors in the regions containing BRCA1, TP53, and NF1 mutations, and an amplification in the regions containing MYC. We did not observe the emergence of any new mutations among tumors from diagnosis to relapse after chemotherapy, suggesting that mutations already present in the primary tumor contributed to metastases and chemotherapy resistance.

Conclusions

Our findings suggest that exome sequencing of matched samples from one patient is a powerful method of detecting somatic mutations and prioritizing their potential role in the development of the disease.

【 授权许可】

   
2013 Zhang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, Bowden G, Kalmyrzaev B, Warren-Perry M, Snape K, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L, Eccles D, Evans DG, Renwick A, Seal S, Lord CJ, Ashworth A, Reis-Filho J, Antoniou AC, Rahman N: Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 2011, 43(9):879-882.
• [2]Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B, Pennington KP, Garcia RL, King M, Swisher EM: Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. PNAS 2011, 108(44):18032-18037.
• [3]The Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474(7353):609-615.
• [4]Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, Fan I, Bradley L, Shaw PA, Narod SA: Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011, 121(2):353-357.
• [5]Bolton KL, Chenevix- Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton DF, Sinilnikova O, BenÃtez J, GarcÃa MJ, Neuhausen S, Gail MH, Hartge P, Peock S, Frost D, Evans DG, Eeles R, Godwin AK, Daly MB, Kwong A, Ma ESK, Lázaro C, Blanco I, Montagna M: Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012, 307(4):382-389.
• [6]Osher DJ, Kushner YB, Arseneau J, Foulkes WD: Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks? J Clin Pathol 2011, 64(10):924-926.
• [7]Lee MS, Green R, Marsillac SM, Coquelle N, Williams RS, Yeung T, Foo D, Hau DD, Hui B, Monteiro ANA, Glover JNM: Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Cancer Res 2010, 70(12):4880-4890.
• [8]Li H, Durbin R: Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009, 25(14):1754-1760.
• [9]Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R: 1000 Genome project data, processing subgroup: the sequence alignment/map format and SAMtools. Bioinformatics 2009, 25(16):2078-2079.
• [10]Wang K, Li M, Hakonarson H: ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010, 38(16):e164-e164.
• [11]Ge B, Gurd S, Gaudin T, Dore C, Lepage P, Harmsen E, Hudson TJ, Pastinen T: Survey of allelic expression using EST mining. Genome Res 2005, 15(11):1584-1591.
• [12]Sathirapongsasuti JF, Lee H, Horst BAJ, Brunner G, Cochran AJ, Binder S, Quackenbush J, Nelson SF: Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics 2011, 27(19):2648-2654.
• [13]Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B: Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Meth 2008, 5(7):621-628.
• [14]Venkatraman ES, Olshen AB: A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007, 23(6):657-663.
• [15]Piek JMJ, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom R, Menko FH, Gille JJP, Jongsma APM, Pals G, Kenemans P, Verheijen RHM: Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001, 195(4):451-456.
• [16]Castellarin M, Milne K, Zeng T, Tse K, Mayo M, Zhao Y, Webb JR, Watson PH, Nelson BH, Holt RA: Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease. J Pathol 2012, 229(4):515-524.
• [17]Sangha N, Wu R, Kuick R, Powers S, Mu D, Fiander D, Yuen K, Katabuchi H, Tashiro H, Fearon ER, Cho KR: Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia 2008, 10(12):1362-1372.
• [18]Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Meth 2010, 7(4):248-249.
• [19]Jones PA, Baylin SB: The epigenomics of cancer. Cell 2007, 128(4):683-692.
• [20]Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3(1):11-22.
• [21]Lord CJ, Ashworth A: The DNA damage response and cancer therapy. Nature 2012, 481(7381):287-294.
• [22]Brown LA, Kalloger SE, Miller MA, Shih I, McKinney SE, Santos JL, Swenerton K, Spellman PT, Gray J, Gilks CB, Huntsman DG: Amplification of 11q13 in ovarian carcinoma. Genes Chromosom Cancer 2008, 47(6):481-489.
• [23]Johannsdottir H, Johannesdottir G, Agnarsson B, Eerola H, Arason A, Johannsson O, Heikkilä P, Egilsson V, Olsson H, Borg A, Nevanlinna H, Barkardottir R: Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables. Anticancer Res 2004, 24(5):2681-2688.